Beskrivelse
0091-150X, DOI: 10.1007/BF02464147, A V AMELIN ET AL: "The combined use of acupuncture and antidepressants for managing the spondylogenic lumbosacral pain syndrome", FARMAKOLOGIYA I TOKSIKOLOGIYA, vol.54, no.5, 1991, pages 12-13, XP055130728, ISSN: 0014-8318, K. NAKAI ET AL: "CONTRIBUTION TO PAIN-RELATED BEHAVIOR BY VARIOUS TYPES OF SPINAL ALPHA 2 ADRENERGIC RECEPTOR IN A RAT MODEL OF TRIGEMINAL NEUROPATHIC PAIN", ANESTHESIA AND ANALGESIA., vol.123, no.3S-Suppl., 1 September 2016 (2016-09-01), page 417, XP055308561, US ISSN: 0003-2999, DOI: 10.1213/01.ane.0000492718.50980.13, A J REPTA ET AL: "Util ization of an enantiomer as a solution to a pharmaceutical problem: Application to solubilization of 1,2 -di(4-piperazine-2,6-dione)propane", JOURNAL OF PHARMACEUTICAL SCIENCES, vol.65, no.2, February 1976 (1976-02), pages 238-242, XP055130861, DOI: 10.1002/jps.260065021, A B Malmberg ET AL: "Contribution of alpha(2) receptor subtypes to nerve injury-induced pain and its regulation by dexmedetomidine", BRITISH JOURNAL OF PHARMACOLOGY, vol.132, no.8, 1 April 2001 (2001-04-01) , pages 1827-1836, XP055308554, ISSN: 0007-1188, PASCAL DE TULLIO ET AL: "Effective resolution of racemic pirlindole at the preparative scale", CHIRALITY, vol.11, no.4, 29 March 1999 (1999-03-29) , pages 261-266, XP055131009, ISSN: 0899-0042, DOI:
10.1002/(SICI)1520-636X(1999)11:4<261::AID -CHIR1>3.3.CO;2-J cited in the application
Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/
Krav
IPC-klasse
Fullmektig i Norge:
Org.nummer: 979993269
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
A B Malmberg ET AL: "Contribution of alpha(2) receptor subtypes to nerve injury-induced pain and its regulation by dexmedetomidine", BRITISH JOURNAL OF PHARMACOLOGY, vol. 132, no. 8, 1 April 2001 (2001-04-01) , pages 1827-1836, XP055308554, ISSN: 0007-1188 (B1)
A J REPTA ET AL: "Utilization of an enantiomer as a solution to a pharmaceutical problem: Application to solubilization of 1,2-di(4-piperazine-2,6-dione)propane", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 65, no. 2, February 1976 (1976-02), pages 238-242, XP055130861, DOI: 10.1002/jps.260065021 (B1)
A V AMELIN ET AL: "The combined use of acupuncture and antidepressants for managing the spondylogenic lumbosacral pain syndrome", FARMAKOLOGIYA I TOKSIKOLOGIYA, vol. 54, no. 5, 1991, pages 12-13, XP055130728, ISSN: 0014-8318 (B1)
WINFRIED HÄUSER ET AL: "Treatment of Fibromyalgia Syndrome With Antidepressants: A Meta-analysis", JAMA, vol. 301, no. 2, 14 January 2009 (2009-01-14), pages 198-209, XP055130756, ISSN: 0098-7484, DOI: 10.1001/jama.2008.944 (B1)
N. I. ANDREEVA ET AL: "Antidepressant-enhanced analgesic action of clonidine", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 31, no. 4, 1 April 1997 (1997-04-01), pages 166-167, XP055130715, ISSN: 0091-150X, DOI: 10.1007/BF02464147 (B1)
PASCAL DE TULLIO ET AL: "Effective resolution of racemic pirlindole at the preparative scale", CHIRALITY, vol. 11, no. 4, 29 March 1999 (1999-03-29) , pages 261-266, XP055131009, ISSN: 0899-0042, DOI: 10.1002/(SICI)1520-636X(1999)11:4<261::AID -CHIR1>3.3.CO;2-J cited in the application (B1)
K. NAKAI ET AL: "CONTRIBUTION TO PAIN-RELATED BEHAVIOR BY VARIOUS TYPES OF SPINAL ALPHA 2 ADRENERGIC RECEPTOR IN A RAT MODEL OF TRIGEMINAL NEUROPATHIC PAIN", ANESTHESIA AND ANALGESIA., vol. 123, no. 3S-Suppl., 1 September 2016 (2016-09-01), page 417, XP055308561, US ISSN: 0003-2999, DOI: 10.1213/01.ane.0000492718.50980.13 (B1)
Statushistorie
| Hovedstatus | Beslutningsdato, detaljstatus |
|---|---|
| EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
| EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
|
Dato
Type korrespondanse
Journal beskrivelse
|
|---|
|
Innkommende
EP Publiseringsdokument fra EPO
|
|
Utgående
EP Batch Varsel om betaling av første årsavgift (3319)
|
|
Utgående
EP Registreringsbrev (3210)
|
|
Innkommende, AR222897263
Søknadsskjema Patent
|
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Betalingshistorikk:
| Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
|---|---|---|---|---|
| Årsavgift 11. avg. år (EP) | 2024.05.10 | 4550 | CLARIVATE IP SERVICES LIMITED | Betalt og godkjent |
| Årsavgift 10. avg. år (EP) | 2023.05.26 | 3200 | ENVOY INTERNATIONAL LIMITED | Betalt og godkjent |
| Årsavgift 9. avg. år (EP) | 2022.05.06 | 2850 | ENVOY INTERNATIONAL LIMITED | Betalt og godkjent |
| Årsavgift 8. avg. år (EP) | 2021.05.25 | 2550 | ENVOY INTERNATIONAL LIMITED | Betalt og godkjent |
| Årsavgift 7. avg. år (EP) | 2020.05.06 | 2200 | ENVOY INTERNATIONAL LIMITED | Betalt og godkjent |
| Årsavgift 6. avg. år (EP) | 2019.05.13 | 2000 | ENVOY INTERNATIONAL LIMITED | Betalt og godkjent |
| Årsavgift 5. avg. år (EP) | 2018.05.30 | 1650 | ENVOY INTERNATIONAL LIMITED | Betalt og godkjent |
| 31718237 expand_more expand_less | 2017.11.22 | 5500 | Bryn Aarflot AS | Betalt |
|
Valideringsgebyr EP-patent
5500 = 1 X 5500
|